New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
11:20 EDTRHHBYEMA committee adopts positive opinion on orphan status for Roche drug
The European Medicines Agency announced that the Committee for Orphan Medicinal Products adopted 15 positive opinions recommending the medicines for designation as orphan medicinal products to the European Commission. Among the recommendations, the committee adopted a positive opinion on a mixture of recombinant human IgG1 monoclonal antibodies against human cytomegalovirus envelope glycoproteins for prevention of congenital cytomegalovirus infection following primary cytomegalovirus infection, from Roche. Reference Link
News For RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
05:30 EDTRHHBYGenentech reports ocrelizumab Phase III studies met primary, secondary endpoints
Subscribe for More Information
June 25, 2015
14:03 EDTRHHBYRoche initiated with a Buy at HSBC
Subscribe for More Information
June 24, 2015
09:07 EDTRHHBYCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
June 17, 2015
07:14 EDTRHHBYProthena announces PRX002 was safe, well tolerated
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use